Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia

被引:42
作者
Novak, U
Grob, TJ
Baskaynak, G
Peters, UR
Aebi, S
Zwahlen, D
Tschan, MP
Kreuzer, KA
Leibundgut, EO
Cajot, JF
Tobler, A
Fey, MF [1 ]
机构
[1] Univ Bern, Inselspital, Inst Med Oncol, Dept Clin Res Med Oncol Haematol, CH-3010 Bern, Switzerland
[2] Humboldt Univ, Charite Virchow Clin, Dept Haematol Oncol, Berlin, Germany
关键词
apoptosis; B-CLL; overexpression; p53; p73;
D O I
10.1023/A:1011153206003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The p73 protein shares structural and functional similarities with the tumour-suppressor p53, but its role in neoplastic transformation is unknown. Alternative splicing leads to the expression of at least nine p73 C-terminal mRNA splice variants (alpha, beta, gamma, delta, epsilon, zeta, eta, eta1, theta). In this survey, we analyse the expression of p73 by real-time quantitative RT-PCR, its known C-terminal variants with an RT-PCR-Southern technique and by Western blot in samples of 51 patients with B-CLL, normal B lymphocytes from eight individuals, and five haematopoetic cell lines. p73 alpha protein expression positively correlated with higher risk B-CLL stages (P = 0.046). Total p73 mRNA expression was higher (P = 0.01) and p73 alpha protein more frequently detected (P = 0.008) in B-CLL compared with normal CD19+-B-lymphocytes. p73 C-terminal mRNA variants were expressed both in B-CLL and in normal B-lymphocytes, but their expression was biased since the gamma (P = 0.041), the theta (P < 0.001), and the eta variant (P = 0.033) prevailed in normal B-lymphocytes. In summary, we conclude that the accumulation of p73, the expression pattern of particular p73 variants and its link to progression may play a distinct role in the molecular pathology B-CLL.
引用
收藏
页码:981 / 986
页数:6
相关论文
共 34 条
[1]   Mdm2 binds p73α without targeting degradation [J].
Bálint, E ;
Bates, S ;
Vousden, KH .
ONCOGENE, 1999, 18 (27) :3923-3929
[2]   B-cell chronic lymphocytic leukemia: A bird of a different feather [J].
Caligaris-Cappio, F ;
Hamblin, TJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :399-408
[3]   National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].
Cheson, BD ;
Bennett, JM ;
Grever, M ;
Kay, N ;
Keating, MJ ;
OBrien, S ;
Rai, KR .
BLOOD, 1996, 87 (12) :4990-4997
[4]  
Chi SG, 1999, CANCER RES, V59, P2791
[5]   p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis [J].
Cordone, I ;
Masi, S ;
Mauro, FR ;
Soddu, S ;
Morsilli, O ;
Valentini, T ;
Vegna, ML ;
Guglielmi, C ;
Mancini, F ;
Giuliacci, S ;
Sacchi, A ;
Mandelli, F ;
Foa, R .
BLOOD, 1998, 91 (11) :4342-4349
[6]  
Corn PG, 1999, CANCER RES, V59, P3352
[7]   Induction of neuronal differentiation by p73 in a neuroblastoma cell line [J].
De Laurenzi, V ;
Raschellá, G ;
Barcaroli, D ;
Annicchiarico-Petruzzelli, M ;
Ranalli, M ;
Catani, MV ;
Tanno, B ;
Costanzo, A ;
Levrero, M ;
Melino, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (20) :15226-15231
[8]   Additional complexity in p73:: induction by mitogens in lymphoid cells and identification of two new splicing variants ε and ζ [J].
De Laurenzi, V ;
Catani, MV ;
Terrinoni, A ;
Corazzari, M ;
Melino, G ;
Costanzo, A ;
Levrero, M ;
Knight, RA .
CELL DEATH AND DIFFERENTIATION, 1999, 6 (05) :389-390
[9]   Two new p73 splice variants, γ and δ, with different transcriptional activity [J].
De Laurenzi, V ;
Costanzo, A ;
Barcaroli, D ;
Terrinoni, A ;
Falco, M ;
Annicchiarico-Petruzzeli, M ;
Levrero, M ;
Melino, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (09) :1763-1768
[10]   Genomic aberrations and survival in chronic lymphocytic leukemia. [J].
Döhner, H ;
Stilgenbauer, S ;
Benner, A ;
Leupolt, E ;
Kröber, A ;
Bullinger, L ;
Döhner, K ;
Bentz, M ;
Lichter, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) :1910-1916